KLDO - Kaleido Bio's KB109 shows benefit in COVID-19 study

Kaleido Biosciences (KLDO) +2% in premarket has announced interim data from K031 non-IND controlled clinical study evaluating Microbiome Metabolic Therapy ((MMT)) candidate KB109 plus Supportive Self Care ((SSC)) in patients with mild to moderate COVID-19 disease.Preliminary analysis (n=176) demonstrates favorable safety and tolerability; for subjects reporting one or more comorbidities, the median time to resolution of the thirteen overall COVID-19 related symptoms was 18 days with KB109 plus SSC and 27 days with SSC alone.The K031 study of 350 subjects is fully enrolled with topline data expected in Q1 of 2021. Topline data from a smaller 50 subject study of KB109 is also expected in Q1 of 2021.

For further details see:

Kaleido Bio's KB109 shows benefit in COVID-19 study